Seletalisib shows therapeutic potential in primary Sjögren’s syndrome
The selective PI3Kδ inhibitor seletalisib demonstrates clinical activity in patients with primary Sjögren’s syndrome (PSS) despite enrolment-related underpowering, as shown in phase II trial data.
Seletalisib shows therapeutic potential in primary Sjögren’s syndrome
19 Oct 2020
